Abstract
Inhibitors in coagulation are acquired antibodies that act by either neutralizing or inhibiting the activity of specific clotting factors or, alternatively, enhancing their degradation and clearance [1]. Clinically, these occur in two pathogenetically distinct scenarios. The first is when these antibodies occur idiopathically, or in association with other disorders like malignancies, pregnancy, drug exposures, or systemic autoimmune disorders. Such autoantibodies (“auto” since they are directed against the affected individual’s own antigens) usually result in a bleeding diathesis as their most common clinical manifestation. Antiphospholipid antibodies (APLA) are a special subset of this group, since their unique properties cause thromboses more often than abnormal bleeding [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hurwitz A, Massone R, Lopez BL. Acquired bleeding disorders. Hematol Oncol Clin North Am. 2017;31(6):1123–45.
Giangrande P. Acquired hemophilia. Monograph published by the World Federation of Hemophilia (WFH) 2005, revised 2012. No. 38; Nov 2012. www.wfh.org/publication/files/pdf-1186.pdf. Accessed 31 Jul 2018.
Ljung RCR. How I manage patients with inherited haemophilia A and B and factor inhibitors. Br J Haematol. 2018;180(4):501–10.
Bain BJ, Bates I, Laffan MA, Lewis SM. Dacie and lewis’ practical haematology. 12/e; 2017.
Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano ME, Shima M, St-Louis J, Lévesque H. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010;3:161.
Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, Tiede A, Kessler CM. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695–705.
Mahendra A, Padiolleau-Lefevre S, Kaveri SV, Lacroix-Desmazes S. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? Br J Haematol. 2012;156(1):3–12.
Ling M, Duncan EM, Rodgers SE, Somogyi AA, Crabb GA, Street AM, Lloyd JV. Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. Br J Haematol. 2001;114(4):861–7.
Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, Morfini M, Santagostino E, Rocino A, AICE Working Group. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015;13(3):498–513.
Depreter B, Devreese KM. Differences in lupus anticoagulant final conclusion through clotting time or Rosner index for mixing test interpretation. Clin Chem Lab Med. 2016;54(9):1511–6.
Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012;157(1):47–58.
Danowski A, Rego J, Kakehasi AM, Funke A, Carvalho JF, Lima IV, Souza AW, Levy RA, Comissão de Vasculopatias da Sociedade Brasileira de Reumatologia. Guidelines for the treatment of antiphospholipid syndrome. Rev Bras Reumatol. 2013;53(2):184–92.
Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G, Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017;76(10):1637–41.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295.
Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7(10):1737–40.
Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol. 2012;87(Suppl 1):S75–81.
Miller CH. Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review. Haemophilia. 2018;24(2):186–97.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A, Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
Brown SA, Barnes C, Curtin J, Dunkley S, Ockelford P, Phillips J, Rowell J, Smith M, Tran H, Hematology Working Group. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. Intern Med J. 2012;42(11):1243–50.
Gringeri A, Mannucci PM, Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia. 2005;11(6):611–9.
Lai J, Hough C, Tarrant J, Lillicrap D. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood. 2017;129(24):3147–54.
Clere AS, Diaz I, Lebreton A, Lavigne-Lissalde G, Schved JF, Biron-Andreani C. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients? Haemophilia. 2014;20(6):e406–8.
Santagostino E, Young G, Carcao M, Mannucci PM, Halimeh S, Austin S. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Rev Hematol. 2018;11(2):87–97.
Rosendaal FR, Palla R, Garagiola I, Mannucci PM, Peyvandi F, SIPPET Study Group. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017;130(15):1757–9.
Lai JD, Lillicrap D. Factor VIII inhibitors: advances in basic and translational science. Int J Lab Hematol. 2017;39(Suppl 1):6–13.
ter Avest PC, Fischer K, Mancuso ME, Santagostino E, Yuste VJ, van den Berg HM, van der Bom JG, CANAL Study Group. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost. 2008;6(12):2048–54.
Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost. 2015;113(5):958–67.
Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia. 2010;16(Suppl 1):13–9.
Ragni MV. Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy. Hematology Am Soc Hematol Educ Program. 2017;2017(1):605–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sharma, P. (2019). Inhibitors in Coagulation. In: Saxena, R., Pati, H. (eds) Hematopathology. Springer, Singapore. https://doi.org/10.1007/978-981-13-7713-6_23
Download citation
DOI: https://doi.org/10.1007/978-981-13-7713-6_23
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-7712-9
Online ISBN: 978-981-13-7713-6
eBook Packages: MedicineMedicine (R0)